Turnaround times for molecular testing of pediatric viral cerebrospinal fluid samples in United Kingdom laboratories.

Autor:	Paul SP; Department of Paediatrics, Yeovil District Hospital, Yeovil BA21 4AT, Somerset, United Kingdom. siba.paul@nhs.net., Balakumar V; School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom., Kirubakaran A; Department of Paediatrics, Hillingdon Hospital, Uxbridge UB8 3NN, United Kingdom., Niharika J; School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom., Heaton PA; Department of Paediatrics, Yeovil District Hospital, Yeovil BA21 4AT, Somerset, United Kingdom., Turner PC; Department of Medical Microbiology, Torbay Hospital, Torquay TQ2 7AA, United Kingdom.
Jazyk:	angličtina
Zdroj:	World journal of clinical pediatrics [World J Clin Pediatr] 2022 Mar 18; Vol. 11 (3), pp. 289-294. Date of Electronic Publication: 2022 Mar 18 (Print Publication: 2022).
DOI:	10.5409/wjcp.v11.i3.289
Abstrakt:	Background: Rapid molecular testing has revolutionized the management of suspected viral meningitis and encephalitis by providing an etiological diagnosis in < 90 min with potential to improve outcomes and shorten inpatient stays. However, use of molecular assays can vary widely. Aim: To evaluate current practice for molecular testing of pediatric cerebrospinal fluid (CSF) samples across the United Kingdom using a structured questionnaire. Methods: A structured telephone questionnaire survey was conducted between July and August 2020. Data was collected on the availability of viral CSF nucleic acid amplification testing (NAAT), criteria used for testing and turnaround times including the impact of the coronavirus disease 2019 pandemic. Results: Of 196/212 (92%) microbiology laboratories responded; 63/196 (32%) were excluded from final analysis as they had no on-site microbiology laboratory and outsourced their samples. Of 133 Laboratories included in the study, 47/133 (35%) had onsite facilities for viral CSF NAAT. Hospitals currently undertaking onsite NAAT ( n = 47) had much faster turnaround times with 39 centers (83%) providing results in ≤ 24 h as compared to those referring samples to neighboring laboratories (5/86; 6%). Conclusion: Onsite/near-patient rapid NAAT (including polymerase chain reaction) is recommended wherever possible to optimize patient management in the acute setting. Competing Interests: Conflict-of-interest statement: None for any of the authors. (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu